help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delitala, G.
Right arrow Articles by Mannelli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delitala, G.
Right arrow Articles by Mannelli, M.

Journal of Clinical Endocrinology & Metabolism, Vol 57, 1145-1149, Copyright © 1983 by Endocrine Society

ARTICLES

Cholinergic receptor control mechanisms for L-dopa, apomorphine, and clonidine-induced growth hormone secretion in man

G Delitala, M Maioli, A Pacifico, S Brianda, M Palermo and M Mannelli

The effect of pirenzepine, an anticholinergic agent, on GH release induced by L-dopa (500 mg po), apomorphine (0.75 mg sc), and clonidine (0.150 mg iv) administration was studied in a group of normal men. Pirenzepine, a cholinergic muscarinic antagonist, completely blocked the GH rise induced by dopamine- and adreno-receptor stimulation. In contrast, the PRL-inhibiting action of L-dopa was not modified by the cholinergic antagonist. The data suggest that acetylcholine and its receptors are important regulators of the neurosecretory mechanisms that control GH secretion in man.


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
W. A. Bauman, S. C. Kirshblum, N. G. Morrison, C. M. Cirnigliaro, R.-L. Zhang, and A. M. Spungen
Effect of Low-Dose Baclofen Administration on Plasma Insulin-like Growth Factor-I in Persons With Spinal Cord Injury.
J. Clin. Pharmacol., April 1, 2006; 46(4): 476 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. Friess, T. Kuempfel, J. Winkelmann, D. Schmid, M. Uhr, R. Rupprecht, F. Holsboer, and C. Trenkwalder
Increased Growth Hormone Response to Apomorphine in Parkinson Disease Compared With Multiple System Atrophy
Arch Neurol, February 1, 2001; 58(2): 241 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
E. E. Muller, V. Locatelli, and D. Cocchi
Neuroendocrine Control of Growth Hormone Secretion
Physiol Rev, April 1, 1999; 79(2): 511 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. Giustina and J. D. Veldhuis
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human
Endocr. Rev., December 1, 1998; 19(6): 717 - 797.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society